Verified peer comparison

ZTS vs LLY

Zoetis Inc. compared with Eli Lilly and Company. This page compares both source-verified company profiles and does not introduce an unverified price target.

ZTS

Zoetis Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

LLY

Eli Lilly and Company

$782.10

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

ZTS: Pharmaceuticals

LLY: Pharmaceuticals

Upside lens

ZTS: Pet owners' focus on longevity and quality of life can sustain medicines, vaccines and diagnostics demand. Librela and Solensia can expand treatment of chronic pain in dogs and cats as veterinarian familiarity grows. New vaccines, diagnostics and monoclonal antibodies can extend a differentiated portfolio.

LLY: obesity drug adoption and pipeline expansion

Risk lens

ZTS: Adverse-event concerns or label changes could slow adoption of important companion-animal products. Clinic staffing constraints and affordability pressure can limit visits, diagnoses and treatment starts. Disease outbreaks, commodity economics and regulation can cause abrupt changes in producer demand.

LLY: supply constraints and valuation expectations